Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;55(2):29-38.
doi: 10.1002/hast.4976.

Rethinking the Burden of Traditional Informed Consent Prior to Prenatal Genetic Screening

Megan Allyse, Kirsten Riggan, Natasha Bonhomme, Marsha Michie

Rethinking the Burden of Traditional Informed Consent Prior to Prenatal Genetic Screening

Megan Allyse et al. Hastings Cent Rep. 2025 Mar.

Abstract

The ethics literature and professional guidelines call for extensive discussions prior to prescreening consent to prenatal cell-free DNA screening to, theoretically, allow patients to make decisions that match their values and goals of care. Most patients, however, actively avoid in-depth moral deliberation when consenting to prenatal screening and then receive a screen-negative result, suggesting that an information-heavy process is irrelevant for average-risk pregnancies. In addition, extensive information-based consent procedures are not feasible in many resource-limited contexts. Meanwhile, patients and families with screen-positive results frequently report minimal support following screening, resulting in long-term distress and suboptimal outcomes. We argue for a fundamental shift to an approach we call "just-in-time consent": identifying the essential information for values-based decisions prior to screening while relocating resources and moral deliberation to when families receive screen-positive results. This model both ensures that patients and families receive support when they most need it and maintains high standards for the ethical provision of prenatal genetic screening.

Keywords: clinical ethics; informed consent; patient support; prenatal care; prenatal genetic screening; shared decision‐making.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Society for Maternal-Fetal Medicine (SMFM) Publications Committee, “#36: Prenatal Aneuploidy Screening Using Cell-free DNA,” American Journal of Obstetrics and Gynecology 212, no. 6 (2015): 711–6. - PubMed
    2. Allyse MA and Wick MJ, “Noninvasive Prenatal Genetic Screening Using Cell-free DNA,” Journal of the American Medical Association 320, no. 6 (2018): 591–2. - PubMed
    1. van den Heuvel A. et al. , “Will the Introduction of Non-Invasive Prenatal Diagnostic Testing Erode Informed Choices? An Experimental Study of Health Care Professionals,” Patient Education and Counseling 78, no. 1 (2010): 24–28. - PubMed
    2. Deans Z. and Newson AJ, “Should Non-Invasiveness Change Informed Consent Procedures for Prenatal Diagnosis?,” Health Care Analysis 19, no. 2 (2011): 122–32. - PubMed
    3. Farrell RM et al. , “Risk and Uncertainty: Shifting Decision Making for Aneuploidy Screening to the First Trimester of Pregnancy,” Genetics and Medicine 13, no. 5 (2011): 429–36. - PubMed
    4. Allyse MA et al. , “Best Ethical Practices for Clinicians and Laboratories in the Provision of Noninvasive Prenatal Testing,” Prenatal Diagnosis 33, no. 7 (2013): 656–61. - PMC - PubMed
    1. Whitney SN, McGuire AL, and McCullough LB, “A Typology of Shared Decision Making, Informed Consent, and Simple Consent,” Annals of Internal Medicine 140, no. 1 (2004): 54. - PubMed
    2. McCullough LB, McGuire AL, and Whitney SN, “Consent: Informed, Simple, Implied and Presumed,” American Journal of Bioethics 7, no. 12 (2007): 49–50. - PubMed
    1. Hue L et al. , “Position Statement from the International Society for Prenatal Diagnosis on the Use of Non-Invasive Prenatal Testing for the Detection of Fetal Chromosomal Conditions in Singleton Pregnancies,” Prenatal Diagnosis 43, no. 7 (2023): 814–28. - PubMed
    2. Verma IC, Dua-Puri R, and Bijarnia-Mahay S, “ACMG 2016 Update on Noninvasive Prenatal Testing for Fetal Aneuploidy: Implications for India,” Journal of Fetal Medicine 4, no. 1 (2017): 1–6.
    3. Allyse MA and Wick MJ, “What Do the New American College of Medical Genetics and Genomics (ACMG) Guidelines Mean for the Provision of Non-Invasive Prenatal Genetic Screening?,” Journal of Obstetrics and Gynaecology 37, no. 6 (2017): 795–8. - PubMed
    4. American College of Obstetricians and Gynecologists, “Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin Summary, Number 226,” Obstetrics and Gynecology 136, no. 4 (2020): 859–67. - PubMed
    1. Riggan KA et al. , “Patient Experiences with Prenatal Cell-Free DNA Screening in a Safety Net Setting,” Prenatal Diagnosis 44, no. 4 (2024): 409–17. - PMC - PubMed

LinkOut - more resources